A new MD Anderson study found that psilocybin protected nerves from chemotherapy in preclinical models. Here is what the research found, what it does not prove yet, and why clinicians at Serenity are paying attention.
THE SHORT ANSWER
What the study found: In preclinical models, psilocybin given before chemotherapy prevented chemotherapy-induced peripheral neuropathy, helped preserve sensory nerve endings, and preserved mitochondrial movement and energy delivery inside nerves.
What the study does not show: It does not prove that psilocybin prevents chemotherapy-related neuropathy in people. Human clinical research is still needed.
Why it matters: The findings broaden the psychedelic-medicine conversation beyond mood and consciousness and raise new questions about the nervous system, neuroprotection, cellular energy, and the relationship between brain and body.
When most people hear about psilocybin research, they think about mental health.
Depression. Anxiety. Trauma. Existential distress. The emotional impact of serious illness.
But a new study from The University of Texas MD Anderson Cancer Center in Houston is asking a very different question:
Could psilocybin help protect the nervous system from damage caused by chemotherapy?
The study, published in Science on September 3, 2026, found that psilocybin given before chemotherapy prevented chemotherapy-induced peripheral neuropathy across several preclinical models. Researchers found evidence that psilocybin helped preserve sensory nerve endings and, perhaps most intriguingly, helped maintain the movement and distribution of mitochondria – the structures cells depend on for energy – inside nerve fibers.
That is a very different conversation from the one most of us are accustomed to having about psychedelic medicine.
And it is one reason this study caught our attention at Serenity Wellness and Counseling Center.
Members of our clinical team participate in multiple psychedelic-assisted therapy research projects outside of Serenity. That work gives us a close view of a field that is rapidly evolving – not only in what these medicines might someday be used for, but also in what they may teach us about the relationship between the brain, body, nervous system, psychological experience, and human capacity for change.
The new MD Anderson research is still early. It does not establish psilocybin as a treatment for chemotherapy-related neuropathy in people.
But what researchers are beginning to uncover is fascinating.
What Did the MD Anderson Psilocybin Study Actually Find?
Chemotherapy-induced peripheral neuropathy, or CIPN, occurs when certain cancer treatments damage nerves. It can lead to numbness, tingling, burning, cold sensitivity, pain, changes in touch sensation, and problems with mobility or balance.
For some people, those symptoms can continue long after chemotherapy ends.
Researchers at MD Anderson tested whether giving psilocybin before chemotherapy could prevent that damage from occurring.
In the preclinical study, psilocybin protected against nerve injury across models involving platinum- and taxane-based chemotherapy drugs. Researchers reported preserved touch sensation and sensory nerve endings, and the protective effects remained through repeated chemotherapy cycles while chemotherapy’s antitumor activity was maintained in the models.
That distinction matters.
The researchers were not simply finding that psilocybin made the animals perceive less pain.
They found evidence suggesting that the nerves themselves were being protected.
That led them to look more closely at how this might be happening.
Why Are Mitochondria Showing Up in a Psilocybin Study?
This may be one of the most interesting parts of the research.
Mitochondria are structures inside our cells that help produce the energy those cells need to function. Nerve cells present a particular challenge because some nerve fibers stretch over long distances. Energy needs to be available where the nerve needs it – not simply produced somewhere else in the cell.
In the MD Anderson study, chemotherapy disrupted the movement and distribution of mitochondria within nerve fibers.
Psilocybin appeared to help preserve that mitochondrial trafficking, allowing energy to continue reaching nerve endings. Researchers identified a biological signaling pathway involved in this process and found that the effect depended on serotonin 5-HT2A receptors.
For people who primarily associate psychedelics with perception, emotions, or unusual experiences, that finding may be surprising.
The study suggests there may be important biological effects occurring outside of what a person consciously experiences.
Researchers provided another interesting clue: a non-hallucinogenic compound that activated the same serotonin receptor produced similar nerve-protective effects in the preclinical models.
Which effects of psychedelic compounds depend upon the psychedelic experience itself, and which may come from biological processes occurring independently of that experience?
We do not yet know all of those answers.
That is exactly why research like this matters.
This Research Is Promising – but It Is Not Yet a Human Treatment
This is an important place to slow down.
The headlines surrounding psychedelic research can sometimes move much faster than the science.
The MD Anderson findings were preclinical. They should not be interpreted to mean that people receiving chemotherapy should take psilocybin to prevent neuropathy.
MD Anderson has announced an upcoming Phase 2 study, NeuroGuard (NCT07227909), to evaluate whether the mechanisms seen in the preclinical work translate into clinically meaningful reductions in chemotherapy-induced peripheral neuropathy in people.
The animal findings tell researchers that the question is worth studying in people. They do not yet tell us what the answer will be.
That distinction is essential.
Psychedelic Research Is Becoming About More Than Mental Health
For years, much of the public conversation around psychedelic medicine has focused on psychiatric and psychological conditions.
That work is continuing. MD Anderson, for example, is also conducting clinical research evaluating psilocybin-assisted psychotherapy for depression and anxiety in people living with advanced cancer and in cancer survivors.
But this newest research illustrates how the field is beginning to expand.
Scientists are asking questions not only about mood and consciousness, but also about the nervous system, pain, neuroplasticity, nerve protection, cellular energy, and the biological mechanisms through which these compounds act.
That broader exploration is important because human beings do not divide neatly into a “mental health side” and a “physical health side.”
The brain is part of the body.
The nervous system affects how we experience and respond to our environment.
Physical health can influence emotional well-being. Stress can influence the body.
Relationships, behavior, sleep, nutrition, physical health, values, meaning, and psychological patterns can interact rather than existing in separate compartments.
That interconnectedness is central to the way we think about whole-person mental health at Serenity. We do not assume every symptom has one hidden cause or that every person needs multiple treatments. Instead, we try to remain curious about the psychological, relational, neurological, physical, behavioral, and lifestyle factors that may be interacting for a particular person.
Why This Research Is Personally Meaningful to Our Team
Psychedelic research is not something our team only follows through journal articles.
Members of our clinical team participate as therapists in multiple psychedelic-assisted therapy research projects conducted within approved clinical research settings.
That experience has allowed us to work closely with the structure surrounding psychedelic-assisted therapy: careful screening, preparation before dosing, support during altered-state experiences, integration afterward, protocol adherence, outcome monitoring, and thoughtful attention to safety.
It has also reinforced something we believe is easy to miss when psychedelic medicines make headlines:
The medicine is not always the entire treatment.
A meaningful experience does not automatically become meaningful change.
People still have relationships to return to. Patterns that have developed over decades. Decisions to make. Behaviors to change. Grief to process. Boundaries to establish. Values they want to live more consistently. Nervous systems that may continue reacting even when someone intellectually understands why.
The work surrounding the experience matters.
We bring many of those lessons into the way we think about Ketamine-Assisted Psychotherapy at Serenity.
What Psychedelic Research Has Taught Us About Our Ketamine Work
Psilocybin and ketamine are different medicines. They act through different pharmacological mechanisms and have different research bases.
We should not take a finding about psilocybin and assume it applies to ketamine.
But working in psychedelic research has influenced something broader about the way we approach medicine-assisted psychotherapy.
We pay attention to what happens before, during, and after the medicine experience.
Preparation can help someone understand what they are entering and begin identifying the patterns, fears, values, or questions they want to explore.
The medicine experience may create an opportunity to encounter those patterns differently.
Integration helps the person consider what emerged and, importantly, how that experience might translate into everyday life.
At Serenity, Ketamine-Assisted Psychotherapy is therefore not viewed simply as receiving a medication and waiting to see whether symptoms change.
When KAP is appropriate, psychotherapy remains an important part of the process.
The question becomes not only: “What did you experience?” but also: “What does this invite you to do differently?”
That distinction has become increasingly important in the way we think about meaningful and sustainable change.
Related Serenity resource: Learn more about our approach to Ketamine-Assisted Psychotherapy.
The MD Anderson Study Also Raises a Bigger Whole-Person Question
The mitochondrial finding caught our attention for another reason.
At Serenity, our whole-person approach has been developing around a simple idea:
If someone remains stuck, it may be worth becoming curious about more than one pathway.
Sometimes psychotherapy is exactly what someone needs.
Sometimes trauma-focused work such as EMDR may be appropriate.
For some people, nervous-system or brain-based approaches such as LENS Neurofeedback may be worth considering.
For others, physical and lifestyle factors such as sleep, stress, nutrition, movement, or other aspects of wellness may also deserve attention.
Our functional wellness work explores some of the physical and lifestyle factors that can interact with mental and emotional well-being. Our therapists address psychological, behavioral, relational, and trauma-related patterns. Other services may focus more directly on nervous-system regulation or brain function.
The purpose is not to assume that everyone needs everything.
What may be contributing to this person’s experience, and where might there be additional pathways for change?
The new MD Anderson findings do not prove that mitochondria are responsible for depression, anxiety, trauma, or other mental health concerns. We should be very careful not to make that leap.
What the research does illustrate is how much remains to be understood about the relationships among cellular function, the nervous system, the brain, physical illness, psychological experience, and the treatments we use.
That kind of curiosity is important.
Related Serenity resources: Explore LENS Neurofeedback, Functional Wellness & Health Coaching, and The Serenity Protocol: A Whole Person Model for Meaningful Change.
Psychedelic Medicine May Have More to Teach Us Than We Expected
Perhaps one of the most exciting things about psychedelic research is that the questions keep changing.
Initially, much of the conversation was:
Can psychedelics help certain mental health conditions?
Now researchers are beginning to ask more detailed questions.
- What happens biologically?
- What changes in the nervous system?
- What role does the subjective experience play?
- Which effects require that altered state, and which do not?
- Could these compounds have applications outside traditional psychiatric treatment?
- How do preparation and integration affect outcomes?
- What allows a temporary period of increased flexibility or altered experience to translate into lasting changes in someone’s everyday life?
We do not have all of those answers.
And responsible psychedelic medicine should be willing to say that.
The goal should not be to turn psychedelics into the next cure-all.
It should be to study them carefully enough to understand what they can do, what they cannot do, who may benefit, who may not, and how they can be used responsibly when evidence supports their use.
Where Serenity Fits Into This Conversation
Serenity Wellness and Counseling Center is located in Cypress, Texas, serving Cypress and the greater Northwest Houston area.
We do not provide psilocybin treatment at Serenity.
Our clinicians’ work with psilocybin occurs within approved clinical research settings.
At Serenity, we provide Ketamine-Assisted Psychotherapy when clinically appropriate and offer other mental health and whole-person services that may include psychotherapy, trauma-focused care, LENS Neurofeedback, functional wellness support, breathwork, somatic approaches, and other individualized pathways.
Our involvement in psychedelic research gives us another perspective to bring into that work.
It encourages us to remain curious.
To respect both psychology and biology.
To distinguish promising research from established treatment.
And to remember that meaningful change is rarely about one molecule, one therapy, one insight, or one explanation.
Sometimes the most useful question is not simply, “What treatment fixes this symptom?” It is, “What is happening in this person as a whole – and what might help create the conditions for meaningful change?”
That is the question research like this continues to push us to ask.
Interested in Learning More About Ketamine-Assisted Psychotherapy?
Serenity Wellness and Counseling Center provides Ketamine-Assisted Psychotherapy in Cypress, Texas, when clinically appropriate. Our approach emphasizes preparation, the therapeutic experience, integration, and helping clients translate insight into meaningful change outside the dosing session.
Learn More About Ketamine-Assisted Psychotherapy
Explore The Serenity Protocol: A Whole Person Model for Meaningful Change
Frequently Asked Questions
Did MD Anderson prove that psilocybin prevents chemotherapy neuropathy in humans?
No. The September 2026 Science study reported compelling results in preclinical models. Human clinical research is needed to determine whether those effects translate to people. MD Anderson has announced a Phase 2 trial to investigate that question.
Does Serenity offer psilocybin therapy?
No. Serenity does not offer psilocybin as a clinical treatment. Members of our clinical team participate in psychedelic-assisted therapy research within approved clinical research settings.
Is psilocybin the same as ketamine?
No. Psilocybin and ketamine are different compounds with different mechanisms, legal statuses, research histories, and clinical applications. Serenity offers Ketamine-Assisted Psychotherapy when clinically appropriate; findings from psilocybin research should not automatically be assumed to apply to ketamine.
Why does Serenity follow psychedelic research?
Members of our team are involved professionally in psychedelic-assisted therapy research, and the field is producing important questions about psychological flexibility, neurobiology, preparation, integration, nervous-system function, and whole-person care. We use what we learn from working within rigorous research settings to inform how we think about responsible medicine-assisted psychotherapy and other services at Serenity.
About the Author
Nicole Bankhead, LPC, is the owner and director of Serenity Wellness and Counseling Center in Cypress, Texas. Her clinical work includes Ketamine-Assisted Psychotherapy, and she participates as a therapist in psychedelic-assisted therapy research conducted within approved clinical research settings. Her work in this area informs Serenity’s emphasis on preparation, integration, psychological flexibility, and whole-person approaches to mental health care.
Continue Exploring
- Why Insight Alone Doesn’t Always Create Change
- Why Preparation and Integration Matter in Psychedelic-Assisted Therapy
- Ketamine and Psilocybin Aren’t the Same: Understanding Different Forms of Medicine-Assisted Therapy
- What Does Whole-Person Mental Health Care Actually Mean?
Sources & Further Reading
- Heles M, Pasvolsky L, Sathishkumar H, et al. Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation. Science. September 3, 2026. DOI: 10.1126/science.aec6116.
- The University of Texas MD Anderson Cancer Center. Psilocybin prevents chemotherapy-related nerve injury and associated symptoms in preclinical models. September 3, 2026.
- ClinicalTrials.gov. NeuroGuard: Psilocybin Trial for Preventing Chemotherapy-Induced Neuropathy. NCT07227909.
- The University of Texas MD Anderson Cancer Center. TRIP – Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy.
- The University of Texas MD Anderson Cancer Center. TRIPS – Psilocybin-Assisted Psychotherapy in Cancer Survivors.
This article is provided for educational purposes and is not medical advice. Psilocybin remains an investigational treatment for the uses discussed in this article. Individuals undergoing cancer treatment should discuss treatment decisions, symptoms, medications, supplements, or investigational therapies with their oncology team.
